| abstract |
An anti-mouse .alpha.9 integrin antibody, an anti-human .alpha.9 integrin antibody, a hybridoma cell producing any of the antibodies, a method of producing any of the antibodies and the hybridoma cell, and a pharmaceutical composition comprising any of the antibodies are provided. The anti-.alpha.9 integrin antibody exerts a therapeutic effect on cancer, for example proliferation and metastasis of a cancer cell, and an inflammatory disease, for example rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease and the like by inhibiting the .alpha.9 integrin function. |